Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Drug–drug interactions between HCV therapy and ART is the primary consideration when selecting DAA therapy in HCV/HIV-coinfected patients
  • The AASLD/IDSA and EASL provide recommendations on the use of certain HCV therapies with ART (Table 12)

Action required